Cargando…

Mechanism and Molecular Targets of Ejiao Siwu Decoction for Treating Primary Immune Thrombocytopenia Based on High-Performance Liquid Chromatograph, Network Pharmacology, Molecular Docking and Cytokines Validation

We explored the mechanisms and molecular targets of Ejiao Siwu Decoction (EJSW) for treating primary immune thrombocytopenia (ITP) using network pharmacology and molecular docking. Active compounds of EJSW were identified by high-performance liquid chromatography-diode array detector (HPLC-DAD) and...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Ming Jing, Sun, Yan, Song, Ying, Ma, Ju Ning, Wang, Zi Qing, Ding, Xiao Qing, Chen, Hai Yan, Zhang, Xue Bin, Song, Min Min, Hu, Xiao Mei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9326259/
https://www.ncbi.nlm.nih.gov/pubmed/35911404
http://dx.doi.org/10.3389/fmed.2022.891230
_version_ 1784757243552464896
author Wang, Ming Jing
Sun, Yan
Song, Ying
Ma, Ju Ning
Wang, Zi Qing
Ding, Xiao Qing
Chen, Hai Yan
Zhang, Xue Bin
Song, Min Min
Hu, Xiao Mei
author_facet Wang, Ming Jing
Sun, Yan
Song, Ying
Ma, Ju Ning
Wang, Zi Qing
Ding, Xiao Qing
Chen, Hai Yan
Zhang, Xue Bin
Song, Min Min
Hu, Xiao Mei
author_sort Wang, Ming Jing
collection PubMed
description We explored the mechanisms and molecular targets of Ejiao Siwu Decoction (EJSW) for treating primary immune thrombocytopenia (ITP) using network pharmacology and molecular docking. Active compounds of EJSW were identified by high-performance liquid chromatography-diode array detector (HPLC-DAD) and high-performance liquid chromatography-mass spectrometry (HPLC-MS) and their targets were obtained from HERB and SwissTargetPrediction, and ITP targets were obtained from Comparative Toxicogenomics Database (CTD) and GeneCards. STRING and Cytoscape were used for protein-protein interaction (PPI) network analysis. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses by WebGestalt yielded a gene-pathway network, Autodock molecular docking was applied to screen targets and active compounds, and cytokines were detected using a cytometric bead array (CBA) human inflammation kit. We identified 14 compounds and 129 targets, and 1,726 ITP targets. RAC-alpha serine/threonine-protein kinase (AKT1), tumour necrosis factor (TNF), interleukin-6 (IL6), caspase-3 (CASP3) and tumour suppressor protein (TP53) were core targets (nodes and edges). Functional annotation identified cofactor binding and coenzyme binding, and 20 significantly enriched pathways. Active compounds of EJSW were successfully docked with ITP targets. Tumour necrosis factor alpha (TNF-α) and interleukin-1 beta (IL-1β) were upregulated in ITP patients, vascular endothelial growth factor A (VEGF-A) and vascular endothelial growth factor D (VEGF-D) were downregulated, and EJSW treatment reversed these trends. EJSW may regulate key ITP targets based on the in silico analyses, and protect vascular integrity through AGE-RAGE signalling, complement and coagulation cascades, and VEGF signalling by downregulating TNF-α, IL-1β and other inflammatory factors.
format Online
Article
Text
id pubmed-9326259
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-93262592022-07-28 Mechanism and Molecular Targets of Ejiao Siwu Decoction for Treating Primary Immune Thrombocytopenia Based on High-Performance Liquid Chromatograph, Network Pharmacology, Molecular Docking and Cytokines Validation Wang, Ming Jing Sun, Yan Song, Ying Ma, Ju Ning Wang, Zi Qing Ding, Xiao Qing Chen, Hai Yan Zhang, Xue Bin Song, Min Min Hu, Xiao Mei Front Med (Lausanne) Medicine We explored the mechanisms and molecular targets of Ejiao Siwu Decoction (EJSW) for treating primary immune thrombocytopenia (ITP) using network pharmacology and molecular docking. Active compounds of EJSW were identified by high-performance liquid chromatography-diode array detector (HPLC-DAD) and high-performance liquid chromatography-mass spectrometry (HPLC-MS) and their targets were obtained from HERB and SwissTargetPrediction, and ITP targets were obtained from Comparative Toxicogenomics Database (CTD) and GeneCards. STRING and Cytoscape were used for protein-protein interaction (PPI) network analysis. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses by WebGestalt yielded a gene-pathway network, Autodock molecular docking was applied to screen targets and active compounds, and cytokines were detected using a cytometric bead array (CBA) human inflammation kit. We identified 14 compounds and 129 targets, and 1,726 ITP targets. RAC-alpha serine/threonine-protein kinase (AKT1), tumour necrosis factor (TNF), interleukin-6 (IL6), caspase-3 (CASP3) and tumour suppressor protein (TP53) were core targets (nodes and edges). Functional annotation identified cofactor binding and coenzyme binding, and 20 significantly enriched pathways. Active compounds of EJSW were successfully docked with ITP targets. Tumour necrosis factor alpha (TNF-α) and interleukin-1 beta (IL-1β) were upregulated in ITP patients, vascular endothelial growth factor A (VEGF-A) and vascular endothelial growth factor D (VEGF-D) were downregulated, and EJSW treatment reversed these trends. EJSW may regulate key ITP targets based on the in silico analyses, and protect vascular integrity through AGE-RAGE signalling, complement and coagulation cascades, and VEGF signalling by downregulating TNF-α, IL-1β and other inflammatory factors. Frontiers Media S.A. 2022-07-13 /pmc/articles/PMC9326259/ /pubmed/35911404 http://dx.doi.org/10.3389/fmed.2022.891230 Text en Copyright © 2022 Wang, Sun, Song, Ma, Wang, Ding, Chen, Zhang, Song and Hu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Wang, Ming Jing
Sun, Yan
Song, Ying
Ma, Ju Ning
Wang, Zi Qing
Ding, Xiao Qing
Chen, Hai Yan
Zhang, Xue Bin
Song, Min Min
Hu, Xiao Mei
Mechanism and Molecular Targets of Ejiao Siwu Decoction for Treating Primary Immune Thrombocytopenia Based on High-Performance Liquid Chromatograph, Network Pharmacology, Molecular Docking and Cytokines Validation
title Mechanism and Molecular Targets of Ejiao Siwu Decoction for Treating Primary Immune Thrombocytopenia Based on High-Performance Liquid Chromatograph, Network Pharmacology, Molecular Docking and Cytokines Validation
title_full Mechanism and Molecular Targets of Ejiao Siwu Decoction for Treating Primary Immune Thrombocytopenia Based on High-Performance Liquid Chromatograph, Network Pharmacology, Molecular Docking and Cytokines Validation
title_fullStr Mechanism and Molecular Targets of Ejiao Siwu Decoction for Treating Primary Immune Thrombocytopenia Based on High-Performance Liquid Chromatograph, Network Pharmacology, Molecular Docking and Cytokines Validation
title_full_unstemmed Mechanism and Molecular Targets of Ejiao Siwu Decoction for Treating Primary Immune Thrombocytopenia Based on High-Performance Liquid Chromatograph, Network Pharmacology, Molecular Docking and Cytokines Validation
title_short Mechanism and Molecular Targets of Ejiao Siwu Decoction for Treating Primary Immune Thrombocytopenia Based on High-Performance Liquid Chromatograph, Network Pharmacology, Molecular Docking and Cytokines Validation
title_sort mechanism and molecular targets of ejiao siwu decoction for treating primary immune thrombocytopenia based on high-performance liquid chromatograph, network pharmacology, molecular docking and cytokines validation
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9326259/
https://www.ncbi.nlm.nih.gov/pubmed/35911404
http://dx.doi.org/10.3389/fmed.2022.891230
work_keys_str_mv AT wangmingjing mechanismandmoleculartargetsofejiaosiwudecoctionfortreatingprimaryimmunethrombocytopeniabasedonhighperformanceliquidchromatographnetworkpharmacologymoleculardockingandcytokinesvalidation
AT sunyan mechanismandmoleculartargetsofejiaosiwudecoctionfortreatingprimaryimmunethrombocytopeniabasedonhighperformanceliquidchromatographnetworkpharmacologymoleculardockingandcytokinesvalidation
AT songying mechanismandmoleculartargetsofejiaosiwudecoctionfortreatingprimaryimmunethrombocytopeniabasedonhighperformanceliquidchromatographnetworkpharmacologymoleculardockingandcytokinesvalidation
AT majuning mechanismandmoleculartargetsofejiaosiwudecoctionfortreatingprimaryimmunethrombocytopeniabasedonhighperformanceliquidchromatographnetworkpharmacologymoleculardockingandcytokinesvalidation
AT wangziqing mechanismandmoleculartargetsofejiaosiwudecoctionfortreatingprimaryimmunethrombocytopeniabasedonhighperformanceliquidchromatographnetworkpharmacologymoleculardockingandcytokinesvalidation
AT dingxiaoqing mechanismandmoleculartargetsofejiaosiwudecoctionfortreatingprimaryimmunethrombocytopeniabasedonhighperformanceliquidchromatographnetworkpharmacologymoleculardockingandcytokinesvalidation
AT chenhaiyan mechanismandmoleculartargetsofejiaosiwudecoctionfortreatingprimaryimmunethrombocytopeniabasedonhighperformanceliquidchromatographnetworkpharmacologymoleculardockingandcytokinesvalidation
AT zhangxuebin mechanismandmoleculartargetsofejiaosiwudecoctionfortreatingprimaryimmunethrombocytopeniabasedonhighperformanceliquidchromatographnetworkpharmacologymoleculardockingandcytokinesvalidation
AT songminmin mechanismandmoleculartargetsofejiaosiwudecoctionfortreatingprimaryimmunethrombocytopeniabasedonhighperformanceliquidchromatographnetworkpharmacologymoleculardockingandcytokinesvalidation
AT huxiaomei mechanismandmoleculartargetsofejiaosiwudecoctionfortreatingprimaryimmunethrombocytopeniabasedonhighperformanceliquidchromatographnetworkpharmacologymoleculardockingandcytokinesvalidation